Request for Nominations for Voting Members for the Genetic Metabolic Diseases Advisory Committee; Amendment of Notice, 12357 [2024-03302]

Download as PDF Federal Register / Vol. 89, No. 33 / Friday, February 16, 2024 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Health Resources and Services Administration National Institutes of Health [Docket No. FDA–2023–N–0008] Advisory Committee on Training in Primary Care Medicine and Dentistry Meeting Cancellation Request for Nominations for Voting Members for the Genetic Metabolic Diseases Advisory Committee; Amendment of Notice AGENCY: ACTION: Health Resources and Services Administration; Department of Health and Human Services. ACTION: Notice of meeting cancellation. AGENCY: Food and Drug Administration, HHS. This is to notify the public that the March 25–26, 2024, meeting of the Advisory Committee on Training in Primary Care Medicine and Dentistry is cancelled. FOR FURTHER INFORMATION CONTACT: Shane Rogers, Designated Federal Officer, Advisory Committee on Training in Primary Care Medicine and Dentistry, 5600 Fishers Lane, Room 15N142, Rockville, Maryland 20857, telephone: (301) 443–5260 or email: srogers@hrsa.gov. SUPPLEMENTARY INFORMATION: This meeting was announced in the Federal Register on Friday, December 15, 2023 (88 FR 86909). Future meetings will be held on August 2, 2024, and another date this calendar year that will be announced at least 30 days before the meeting date through the Federal Register. SUMMARY: Notice. The Food and Drug Administration (FDA) is announcing an amendment to the notice of the request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee (the Committee) in the Center for Drug Evaluation and Research. This request for nominations was announced in the Federal Register of December 13, 2023. The amendment is being made to reflect a change in the DATES portion of the document. There are no other changes. SUMMARY: FOR FURTHER INFORMATION CONTACT: Moon Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301–796–2894, email: GEMDAC@fda.hhs.gov. In the Federal Register of December 13, 2023 (88 FR 86337), FDA announced a request for nominations for voting members excluding consumer and industry representatives, to serve on the Genetic Metabolic Diseases Advisory Committee. On page 86337, in the second column, the DATES portion of the document is changed to read as follows: Nominations received on or before March 12, 2024, will be given first consideration for membership on the Committee. Nominations received after March 12, 2024, will be considered for nomination to the Committee as later vacancies occur. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. SUPPLEMENTARY INFORMATION: lotter on DSK11XQN23PROD with NOTICES1 12357 Maria G. Button, Director, Executive Secretariat. [FR Doc. 2024–03261 Filed 2–15–24; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine; Notice of Meeting Amended Notice of Meeting Notice is hereby given of a change in the virtual meeting of the Biomedical Library, Informatics and Data Science Review Committee, May 17–18, 2024, which was published in the Federal Register on December 21, 2023, 2023, 88 FR 88407. The meeting will be amended to change the meeting dates from March 7– 8, 2024, to March 7, 2024. The meeting will be closed to the public. Dated: February 12, 2024. Lauren K. Roth, Associate Commissioner for Policy. Dated: February 12, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–03302 Filed 2–15–24; 8:45 am] [FR Doc. 2024–03212 Filed 2–15–24; 8:45 am] BILLING CODE 4164–01–P BILLING CODE 4140–01–P VerDate Sep<11>2014 17:24 Feb 15, 2024 Jkt 262001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Integration of Novel Measures for Improved Classification of Type 2 Diabetes Consortium Review. Date: March 19, 2024. Time: 10:30 a.m. to 6:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, NIDDK Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892–2542, 301–594–2242, jerkinsa@niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: February 12, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–03211 Filed 2–15–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as E:\FR\FM\16FEN1.SGM 16FEN1

Agencies

[Federal Register Volume 89, Number 33 (Friday, February 16, 2024)]
[Notices]
[Page 12357]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03302]



[[Page 12357]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-0008]


Request for Nominations for Voting Members for the Genetic 
Metabolic Diseases Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of the request for nominations for voting 
members excluding consumer and industry representatives, to serve on 
the Genetic Metabolic Diseases Advisory Committee (the Committee) in 
the Center for Drug Evaluation and Research. This request for 
nominations was announced in the Federal Register of December 13, 2023. 
The amendment is being made to reflect a change in the DATES portion of 
the document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Moon Choi, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894, email: 
[email protected].

SUPPLEMENTARY INFORMATION: In the Federal Register of December 13, 2023 
(88 FR 86337), FDA announced a request for nominations for voting 
members excluding consumer and industry representatives, to serve on 
the Genetic Metabolic Diseases Advisory Committee. On page 86337, in 
the second column, the DATES portion of the document is changed to read 
as follows:
    Nominations received on or before March 12, 2024, will be given 
first consideration for membership on the Committee. Nominations 
received after March 12, 2024, will be considered for nomination to the 
Committee as later vacancies occur.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: February 12, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-03302 Filed 2-15-24; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.